Biotechnology industry in Italy: Difference between revisions
Content deleted Content added
No edit summary |
|||
| Line 17: | Line 17: | ||
===Agencies=== |
===Agencies=== |
||
* Federchimica Assobiotec |
|||
== Science parks and incubators == |
== Science parks and incubators == |
||
Revision as of 20:28, 3 August 2020
Biotechnology industry in Italy is a highly innovative and fast growing sector dedicated to research. At the end of 2019, there are 696 biotech companies active in Italy.[1]
Industry
Healthcare
Vaccine
- The first Ebola vaccine in the world was developed in the IRBM Science Park laboratories, Pomezia, Rome, Italy.[2]
In the laboratories of the IRBM Science Park a team of Italian and American researchers has developed the Chad3Ebola-Zaire anti-ebola vaccine, a monovalent adenovirus capable of neutralizing the «Zaire» strain of the virus, conceived and produced by OKAIROS, a biotech company founded by Prof. Riccardo Cortese, with whom IRBM set up the Advent equal joint venture.
- A COVID-19 vaccine was developed in the IRBM Science Park laboratories, Pomezia, Rome, Italy in cooperation with Jenner Institute Oxford University.[3][4]
Agricultural biotechnology
Organizations
Ministries
Agencies
- Federchimica Assobiotec
Science parks and incubators
- Istituto di Ricerca di Biologia Molecolare P. Angeletti SpA (IRBM)
- IRBM Science Park
See also
References
- ^ "La fotografia delle imprese di biotecnologie in Italia". assobiotec.federchimica.it. assobiotec.federchimica.it. Retrieved 3 August 2020.
- ^ "Ebola, con il vaccino sviluppato in italia si ottiene l'immunità per 10 mesi". La Repubblica. 7 September 2014. Retrieved 26 November 2015.
- ^ "Vaccino Oxford-Pomezia, a settembre 400 milioni di dosi: accordo con multinazionale Astrazeneca. Fondi anche dagli Usa". ilmessaggero.it. ilmessaggero.it. Retrieved 3 August 2020.
- ^ "The Jenner Institute signs an agreement with Advent to develop a novel coronavirus vaccine". IRBM.
